Kumar Krishna Pradeep, Madhusoodanan Maneesha, Pangath Meghna, Menon Deepthy
Amrita School of Nanosciences & Molecular Medicine, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India.
Drug Deliv Transl Res. 2025 Jun;15(6):1877-1906. doi: 10.1007/s13346-024-01765-w. Epub 2025 Jan 31.
Epithelial ovarian cancer is the most prevalent gynecological malignancy, characterized by high mortality rates due to its late-stage diagnosis and frequent recurrence. The current standard of care for ovarian cancer is a combination of debulking surgery followed by the conventional mode of chemotherapy. Despite significant advances in therapeutic modalities, the overall survival rate of EOC continues to be poor, mainly because low concentrations of the chemotherapeutics reach the peritoneum, which is the primary site of ovarian cancer, leading to disease relapse. Here, intraperitoneal chemotherapy gains advantage due to its ability to deliver the drug molecules directly to the peritoneal cavity and provide localized and sustained effects. This is facilitated by the use of diverse kinds of nano or micron sized delivery systems, which help in transporting drugs, vaccines, antibodies and genes appropriately to the peritoneum for its desired function. This review article delves on how intraperitoneal delivery impacts the therapy of epithelial ovarian cancer spanning the conventional therapeutic modes to the recent nanoinnovations in chemotherapy, immunotherapy and gene therapy.
上皮性卵巢癌是最常见的妇科恶性肿瘤，因其晚期诊断和频繁复发而死亡率高。目前卵巢癌的标准治疗方案是肿瘤减灭术联合传统化疗模式。尽管治疗方式取得了显著进展，但上皮性卵巢癌的总体生存率仍然很低，主要是因为化疗药物到达卵巢癌主要发生部位——腹膜的浓度较低，导致疾病复发。在此，腹腔内化疗具有优势，因为它能够将药物分子直接递送至腹腔并提供局部和持续的作用。使用各种纳米或微米尺寸的递送系统有助于实现这一点，这些系统有助于将药物、疫苗、抗体和基因适当地运输至腹膜以发挥其预期功能。这篇综述文章深入探讨了腹腔内给药如何影响上皮性卵巢癌的治疗，涵盖了从传统治疗模式到化疗、免疫治疗和基因治疗中最新的纳米创新。
